BACKGROUND: Age at diagnosis is an important risk factor in neuroblastoma (NB) with worse prognosis in children older than 18 months. A more indolent course with long-term relapses and fatal outcome has been described in small series of adolescents. Our objective was to describe biological factors that contribute to this particular behaviour and could be helpful in their treatment. PROCEDURE: NB cases older than 10 years of age at diagnosis registered in the files of the Neuroblastoma Group of SEOP from 1992 to 2007 were included. Disease extension was classified according to the International Neuroblastoma Staging System (INSS). Tumour samples were studied according to the International Neuroblastoma Pathology Classification (INPC). Biological studies included MNA, 1p, 11q and 17q status and ploidy. RESULTS: Twenty-two patients, from 10.1 to 24.6 years old, were included. Advanced stages predominated. 14/17 patients presented unfavourable histology. None had NMA or 1p del. However, 11q del was found in 8/13 cases and 17q gain in 7/11. Overall survival (OS) and event-free survival (EFS) for the entire series at 5 years were 0.45 and 0.32, respectively. Moreover, 5-year OS and EFS for stage 4 patients were 0.33 and 0.15. CONCLUSIONS: NB in adolescents is a special subgroup characterised by high-risk prognostic features which differ from those seen in younger patients, especially in relation to genetic abnormalities. The outcome in stage 4 was worse than in younger metastatic children, outlining the need for new therapeutic approaches in this subgroup of patients. The exact cut-off to separate older patients has not yet been established and will probably be based on biology.
BACKGROUND: Age at diagnosis is an important risk factor in neuroblastoma (NB) with worse prognosis in children older than 18 months. A more indolent course with long-term relapses and fatal outcome has been described in small series of adolescents. Our objective was to describe biological factors that contribute to this particular behaviour and could be helpful in their treatment. PROCEDURE: NB cases older than 10 years of age at diagnosis registered in the files of the Neuroblastoma Group of SEOP from 1992 to 2007 were included. Disease extension was classified according to the International Neuroblastoma Staging System (INSS). Tumour samples were studied according to the International Neuroblastoma Pathology Classification (INPC). Biological studies included MNA, 1p, 11q and 17q status and ploidy. RESULTS: Twenty-two patients, from 10.1 to 24.6 years old, were included. Advanced stages predominated. 14/17 patients presented unfavourable histology. None had NMA or 1p del. However, 11q del was found in 8/13 cases and 17q gain in 7/11. Overall survival (OS) and event-free survival (EFS) for the entire series at 5 years were 0.45 and 0.32, respectively. Moreover, 5-year OS and EFS for stage 4 patients were 0.33 and 0.15. CONCLUSIONS: NB in adolescents is a special subgroup characterised by high-risk prognostic features which differ from those seen in younger patients, especially in relation to genetic abnormalities. The outcome in stage 4 was worse than in younger metastatic children, outlining the need for new therapeutic approaches in this subgroup of patients. The exact cut-off to separate older patients has not yet been established and will probably be based on biology.
Authors: Edward F Attiyeh; Wendy B London; Yael P Mossé; Qun Wang; Cynthia Winter; Deepa Khazi; Patrick W McGrady; Robert C Seeger; A Thomas Look; Hiroyuki Shimada; Garrett M Brodeur; Susan L Cohn; Katherine K Matthay; John M Maris Journal: N Engl J Med Date: 2005-11-24 Impact factor: 91.245
Authors: Jo Vandesompele; Michael Baudis; Katleen De Preter; Nadine Van Roy; Peter Ambros; Nick Bown; Christian Brinkschmidt; Holger Christiansen; Valérie Combaret; Maria Lastowska; James Nicholson; Anne O'Meara; Dominique Plantaz; Raymond Stallings; Bénédicte Brichard; Caroline Van den Broecke; Sylvia De Bie; Anne De Paepe; Geneviève Laureys; Frank Speleman Journal: J Clin Oncol Date: 2005-04-01 Impact factor: 44.544
Authors: G M Brodeur; J Pritchard; F Berthold; N L Carlsen; V Castel; R P Castelberry; B De Bernardi; A E Evans; M Favrot; F Hedborg Journal: J Clin Oncol Date: 1993-08 Impact factor: 44.544
Authors: I M Ambros; J Benard; M Boavida; N Bown; H Caron; V Combaret; J Couturier; C Darnfors; O Delattre; J Freeman-Edward; C Gambini; N Gross; C M Hattinger; A Luegmayr; J Lunec; T Martinsson; K Mazzocco; S Navarro; R Noguera; S O'Neill; U Potschger; S Rumpler; F Speleman; G P Tonini; A Valent; N Van Roy; G Amann; B De Bernardi; P Kogner; R Ladenstein; J Michon; A D J Pearson; P F Ambros Journal: J Clin Oncol Date: 2003-06-01 Impact factor: 44.544
Authors: Eva Villamón; Marta Piqueras; Carlos Mackintosh; Javier Alonso; Enrique de Alava; Samuel Navarro; Rosa Noguera Journal: Virchows Arch Date: 2008-06-24 Impact factor: 4.064
Authors: Vid Mlakar; Simona Jurkovic Mlakar; Gonzalo Lopez; John M Maris; Marc Ansari; Fabienne Gumy-Pause Journal: Mol Cancer Date: 2017-06-29 Impact factor: 27.401
Authors: Antonio Juan Ribelles; Sandra Barberá; Yania Yáñez; Pablo Gargallo; Vanessa Segura; Bárbara Juan; Rosa Noguera; Marta Piqueras; Victoria Fornés-Ferrer; Jaime Font de Mora; Adela Cañete; Victoria Castel Journal: Sci Rep Date: 2019-09-24 Impact factor: 4.379
Authors: Jun S Wei; Peter Johansson; Li Chen; Young K Song; Catherine Tolman; Samuel Li; Laura Hurd; Rajesh Patidar; Xinyu Wen; Thomas C Badgett; Adam T C Cheuk; Jean-Claude Marshall; Patricia S Steeg; José P Vaqué Díez; Yanlin Yu; J Silvio Gutkind; Javed Khan Journal: PLoS One Date: 2013-10-16 Impact factor: 3.240
Authors: Ana P Berbegall; Eva Villamón; Irene Tadeo; Tommy Martinsson; Adela Cañete; Victoria Castel; Samuel Navarro; Rosa Noguera Journal: Neoplasia Date: 2014-06 Impact factor: 5.715